Due to a system-wide technology update, we are experiencing extremely high call volume. We appreciate your patience with our operators during this time. Thank you for choosing Fox Chase Cancer Center.

 

Important Public Notice: ANCC Magnet Recognition Program® - Site Visit through November 4, 2022. Click here to learn more.

MENU

Tarlatamab Shows Efficacy Against Metastatic Small Cell Lung Cancer in Phase 1 Study

August 8, 2022

Hossein Borghaei, DO, MS, chief of Thoracic Medical Oncology, working with a patient.Hossein Borghaei, DO, MS, chief of Thoracic Medical Oncology, working with a patient.

PHILADELPHIA (August 8, 2022)—Patients with metastatic small cell lung cancer (SCLC) have limited options for treatment, with few drugs available for patients who have already completed frontline chemotherapy and immunotherapy. Now a global multi-institutional study that included researchers from Fox Chase Cancer Center has shown that the investigational drug tarlatamab is a promising new potential treatment for SCLC.

The phase 1 clinical human trial found that tarlatamab was reasonably effective and had manageable levels of toxicity. Among patients who responded to the drug, the treatment had good durability.

“Finding treatments that are effective in metastatic small cell lung cancer has been challenging, just because this is a very, very aggressive disease,” said Hossein Borghaei, DO, MS, chief of Thoracic Medical Oncology and a professor in the Department of Hematology/Oncology at Fox Chase. “So this drug, if successful, would address a significant unmet need.”

Researchers previously shared data from the study at other medical meetings, and their update, “Phase 1 Updated Exploration and First Expansion Data for DLL3-Targeted T-Cell Engager Tarlatamab in Small Cell Lung Cancer,” was presented at the World Conference on Lung Cancer in Vienna, Austria.

Tarlatamab brings a unique approach to treating SCLC because it’s a bispecific drug called a BiTE molecule. That means it has two arms that bind to two different targets. One end of the molecule is designed to grab hold of a marker that appears on the tumor cells, while the other is designed to grip a component of immune cells.

“By bringing the immune cells and tumor cells in close proximity, the drug is able to activate the immune system at the site of the cancer,” Borghaei said.

A total of 106 patients were enrolled in the trial. Participants received the drug intravenously every two weeks, with patients whose tumors improved receiving step dosing. Twenty-four patients saw a confirmed response, including two with a complete response. The median duration of response was 13 months.

The drug also showed some toxicity, and 92% of patients experienced side effects. Some patients experienced cytokine release syndrome (CRS), an inflammatory syndrome caused by an aggressive immune response. CRS was generally grade 1. Treatment-related grade 2 CRS occurred in 12 patients (11.8%) and grade 3 in one patient (1%). Some patients also experienced neurologic events.

Follow-up studies are planned, with investigators currently meeting to discuss next steps.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Connect with Fox Chase